Piper Sandler analyst Christopher Raymond maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price target from $107 to $122.
Piper Sandler Maintains Overweight on Biomarin Pharmaceutical, Raises Price Target to $122
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.